



## NEWS RELEASE

**For Further Information Contact:**

Nymox Pharmaceutical Corporation  
Roy Wolvin, 800/93NYMOX OR  
info@nymox.com  
www.nymox.com

Alan Stone & Company, LLC  
Alan Stone, 212/521-4102  
astone@alanstone.com  
www.AlanStone.com

**For Immediate Release:**

### **WallStreet Research Releases Buy Recommendation for Nymox Pharmaceutical Corporation**

HASBROUCK HEIGHTS, NJ – July 23, 2007 – Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that WallStreet Research has released an updated analyst report covering the Company's shares with a speculative buy recommendation. The report on Nymox Pharmaceutical and additional information about WallStreet Research is available at [www.WallStreetResearch.org](http://www.WallStreetResearch.org).

According to the WallStreet Research report “we consider the NYMX shares a good speculative buy for near term investors”, and “the Company appears to be an excellent buying opportunity for speculative long term investors seeking emerging biotech stocks.”

Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. The Company is in late stage development of NX-1207, a drug for benign prostatic hyperplasia (BPH). Nymox has a number of drugs in development for E. coli infection, Alzheimer's disease, oncology, and infectious disease. The Company markets NicAlert™ and TobacAlert™ tests for measuring tobacco product exposure, and AlzhemAlert™, a test to aid in the diagnosis of Alzheimer's disease.

WallStreet Research is a prominent research boutique led by Alan Stone, Managing Director of Alan Stone & Company, LLC. Mr. Stone was formerly a securities analyst and assistant portfolio manager at Merrill Lynch Asset Management and an investment analyst at Prudential Insurance Company's Capital Markets Group. The firm has offices in Los Angeles, CA, Palm Beach, FL, and New York City, NY.

Additional information regarding Nymox Pharmaceutical is available on the company's Web site at [www.nymox.com](http://www.nymox.com), email: [info@nymox.com](mailto:info@nymox.com), or at (800) 936-9669, and in the WallStreet Research report at [www.WallStreetResearch.org](http://www.WallStreetResearch.org).

*This press release contains certain “forward-looking statements” as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.*

*The information presented in the WallStreet Research report is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities referred to herein or otherwise. Readers are encouraged to conduct their own due diligence and review all of the company's financial statements and risks statements on file with the SEC. Nymox Pharmaceutical Corporation has paid a fee to Alan Stone & Company, LLC in conjunction with the preparation and distribution of this report, the terms of which are disclosed in full in the report and on the website at [www.WallStreetResearch.org](http://www.WallStreetResearch.org). Alan Stone & Company, LLC or its associates may own shares, for investment purposes, in its corporate accounts, and may increase or decrease its positions at any time, without notice.*